Overview

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Status:
Withdrawn
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Minimally Invasive Surgery Center
Treatments:
Capecitabine
Oxaliplatin